Please login to the form below

Not currently logged in
Email:
Password:

CMA

This page shows the latest CMA news and features for those working in and with pharma, biotech and healthcare.

Aspen to pay millions to NHS following drug pricing investigation

Aspen to pay millions to NHS following drug pricing investigation

South African pharma company Aspen is set to pay the NHS £8m ($9.9m) in the next few weeks, after an investigation by the UK’s Competition and Markets Authority (CMA) ... According to the CMA, thousands of patients rely on the medicine, which is used

Latest news

  • Concordia accused of overcharging NHS for thyroid drug Concordia accused of overcharging NHS for thyroid drug

    Markets Authority (CMA), which says Concordia “abused its dominant position to overcharge the NHS”. ... Concordia said it is “working to better understand the CMA's position and will continue to work constructively to resolve these matters”.

  • MSD probed by UK for blocking Remicade biosimilars MSD probed by UK for blocking Remicade biosimilars

    The Competition and Markets Authority (CMA) issued a ‘statement of objections’ against the pharma company - known as Merck &Co in North America - saying that the discount scheme for Remicade (infliximab) was ... The action is the latest in a series

  • EU starts investigation of Aspen's cancer drug pricing EU starts investigation of Aspen's cancer drug pricing

    Last December, Pfizer was fined £84m by the Competitions and Markets Authority (CMA) for conspiring with Flynn Pharma to raise the price of epilepsy drug phenytoin, and the CMA has since

  • Pfizer gets record £84m fine for hiking price of epilepsy drug Pfizer gets record £84m fine for hiking price of epilepsy drug

    US firm plans to appeal after CMA finds it raised NHS fee by 2, 600% in 2012. ... The Competition and Markets Authority (CMA) has levied an £84.2m fine on Pfizer - as well as a £5.2m penalty for distributor Flynn Pharma - saying they hiked the price of

  • UK government fines GSK over 'pay-for-delay' deals UK government fines GSK over 'pay-for-delay' deals

    The CMA's decision relates to activities between 2001 and 2004 in which GSK agreed to pay £50m to companies supplying generic versions of Seroxat (paroxetine) in order to delay their ... GSK says it rejects the CMA's interpretation of the events. In a

More from news
Approximately 2 fully matching, plus 8 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Streaming Well

Streaming Well is a healthcare-focused, award-winning video production company which operates in the US and Europe. We create engaging visual...

Latest intelligence

eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...
What is changing in cardiovascular disease care?
Paul Midgley, of Wilmington Healthcare, explores the NHS Long-term Plan’s strategy for tackling cardiovascular disease and what it means for pharma...

Infographics